Leptin as a marker for chemo sensitivity in new AML
Part of Blood & lymphatic, Cancer clinical trials.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of acute myeloid leukemia (AML) that hasn't been treated yet.
- You need to be accompanied by a family member when you join the study.
- You cannot have other cancers that need treatment.
- You must not have serious infections like hepatitis, HIV, or SARS.
- You should not have had major surgery in the last 3 weeks.
- Your overall health and daily activity level must be good (score of 0–3 on a standard scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This study looks at how cholesterol levels and body weight affect outcomes in adults with newly diagnosed acute myeloid leukemia (AML), a type of blood cancer. It aims to find if these factors influence how well treatment works.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
Hear when a new Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.